Cargando…

Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development

Renal cell carcinoma (RCC) is one of the leading causes of death in men. Messenger ribonucleic acid (mRNA) vaccines may be an attractive means to achieve satisfactory results. Cancer immunotherapy is a promising cancer treatment strategy. However, immunotherapy is not widely used in renal cell carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinglin, Zhang, Tongtong, Zhai, Xinyu, Wan, Zhong, Ge, Minyao, Liu, Chengzong, Tan, Mingyue, Xu, Dongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669058/
https://www.ncbi.nlm.nih.gov/pubmed/36405755
http://dx.doi.org/10.3389/fimmu.2022.1037808
_version_ 1784832048414851072
author Chen, Xinglin
Zhang, Tongtong
Zhai, Xinyu
Wan, Zhong
Ge, Minyao
Liu, Chengzong
Tan, Mingyue
Xu, Dongliang
author_facet Chen, Xinglin
Zhang, Tongtong
Zhai, Xinyu
Wan, Zhong
Ge, Minyao
Liu, Chengzong
Tan, Mingyue
Xu, Dongliang
author_sort Chen, Xinglin
collection PubMed
description Renal cell carcinoma (RCC) is one of the leading causes of death in men. Messenger ribonucleic acid (mRNA) vaccines may be an attractive means to achieve satisfactory results. Cancer immunotherapy is a promising cancer treatment strategy. However, immunotherapy is not widely used in renal cell carcinoma, as only a few patients show a positive response. The present study aimed to identify potential antigens associated with renal cell carcinoma to develop an anti-renal cell carcinoma mRNA vaccine. Moreover, the immune subtypes of renal cell carcinoma cells were determined. The Cancer Genome Atlas (TCGA) analysis revealed gene expression profiles and clinical information. Antigen-presenting cells infiltrated the immune system using Tumor Immune Estimation Resource (TIMER) tool (http://timer.cistrome.org/). GDSC (Genomics of Drug Sensitivity in Cancer) database were used to estimate drug sensitivity. The 13 immune-related genes discovery could be targets for immunotherapy in renal cell carcinoma patients, as they were associated with a better prognosis and a higher level of antigen-presenting cells. These immune subtypes have significant relationships with immunological checkpoints, immunogenic cell death regulators, and RCC prognostic variables. Furthermore, DBH-AS1 was identified as a potential antigen for developing an mRNA vaccine. The CCK8 assay demonstrated that the proliferative capacity of 786-O and Caki-1 cells overexpressing DBH-AS1 was higher than in the control group. In addition, transwell assay revealed that 786-O and Caki-1 cells overexpressing DBH-AS1 showed higher invasion capacity compared with control. This study provides a theoretical basis for the development of mRNA vaccines. Our findings suggest that DBH-AS1 could be potential antigens for developing RCC mRNA vaccines.
format Online
Article
Text
id pubmed-9669058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96690582022-11-18 Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development Chen, Xinglin Zhang, Tongtong Zhai, Xinyu Wan, Zhong Ge, Minyao Liu, Chengzong Tan, Mingyue Xu, Dongliang Front Immunol Immunology Renal cell carcinoma (RCC) is one of the leading causes of death in men. Messenger ribonucleic acid (mRNA) vaccines may be an attractive means to achieve satisfactory results. Cancer immunotherapy is a promising cancer treatment strategy. However, immunotherapy is not widely used in renal cell carcinoma, as only a few patients show a positive response. The present study aimed to identify potential antigens associated with renal cell carcinoma to develop an anti-renal cell carcinoma mRNA vaccine. Moreover, the immune subtypes of renal cell carcinoma cells were determined. The Cancer Genome Atlas (TCGA) analysis revealed gene expression profiles and clinical information. Antigen-presenting cells infiltrated the immune system using Tumor Immune Estimation Resource (TIMER) tool (http://timer.cistrome.org/). GDSC (Genomics of Drug Sensitivity in Cancer) database were used to estimate drug sensitivity. The 13 immune-related genes discovery could be targets for immunotherapy in renal cell carcinoma patients, as they were associated with a better prognosis and a higher level of antigen-presenting cells. These immune subtypes have significant relationships with immunological checkpoints, immunogenic cell death regulators, and RCC prognostic variables. Furthermore, DBH-AS1 was identified as a potential antigen for developing an mRNA vaccine. The CCK8 assay demonstrated that the proliferative capacity of 786-O and Caki-1 cells overexpressing DBH-AS1 was higher than in the control group. In addition, transwell assay revealed that 786-O and Caki-1 cells overexpressing DBH-AS1 showed higher invasion capacity compared with control. This study provides a theoretical basis for the development of mRNA vaccines. Our findings suggest that DBH-AS1 could be potential antigens for developing RCC mRNA vaccines. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669058/ /pubmed/36405755 http://dx.doi.org/10.3389/fimmu.2022.1037808 Text en Copyright © 2022 Chen, Zhang, Zhai, Wan, Ge, Liu, Tan and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Xinglin
Zhang, Tongtong
Zhai, Xinyu
Wan, Zhong
Ge, Minyao
Liu, Chengzong
Tan, Mingyue
Xu, Dongliang
Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title_full Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title_fullStr Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title_full_unstemmed Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title_short Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
title_sort identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669058/
https://www.ncbi.nlm.nih.gov/pubmed/36405755
http://dx.doi.org/10.3389/fimmu.2022.1037808
work_keys_str_mv AT chenxinglin identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT zhangtongtong identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT zhaixinyu identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT wanzhong identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT geminyao identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT liuchengzong identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT tanmingyue identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment
AT xudongliang identifyingtumorantigensandimmunesubtypesofrenalcellcarcinomaforimmunotherapydevelopment